scholarly journals Reconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer Therapy

2018 ◽  
Vol 9 ◽  
Author(s):  
Sangram Raut ◽  
Linda Mooberry ◽  
Nirupama Sabnis ◽  
Ashwini Garud ◽  
Akpedje Serena Dossou ◽  
...  
Pharmaceutics ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 122 ◽  
Author(s):  
Rebekah Omarkhail Elliott ◽  
Mei He

Since the 2013 Nobel Prize was awarded for the discovery of vesicle trafficking, a subgroup of nanovesicles called exosomes has been driving the research field to a new regime for understanding cellular communication. This exosome-dominated traffic control system has increased understanding of many diseases, including cancer metastasis, diabetes, and HIV. In addition to the important diagnostic role, exosomes are particularly attractive for drug delivery, due to their distinctive properties in cellular information transfer and uptake. Compared to viral and non-viral synthetic systems, the natural, cell-derived exosomes exhibit intrinsic payload and bioavailability. Most importantly, exosomes easily cross biological barriers, obstacles that continue to challenge other drug delivery nanoparticle systems. Recent emerging studies have shown numerous critical roles of exosomes in many biological barriers, including the blood–brain barrier (BBB), blood–cerebrospinal fluid barrier (BCSFB), blood–lymph barrier (BlyB), blood–air barrier (BAB), stromal barrier (SB), blood–labyrinth barrier (BLaB), blood–retinal barrier (BRB), and placental barrier (PB), which opens exciting new possibilities for using exosomes as the delivery platform. However, the systematic reviews summarizing such discoveries are still limited. This review covers state-of-the-art exosome research on crossing several important biological barriers with a focus on the current, accepted models used to explain the mechanisms of barrier crossing, including tight junctions. The potential to design and engineer exosomes to enhance delivery efficacy, leading to future applications in precision medicine and immunotherapy, is discussed.


2020 ◽  
Vol 8 (10) ◽  
pp. 2115-2122 ◽  
Author(s):  
Xia Yang ◽  
Jinxia An ◽  
Zhong Luo ◽  
Rui Yang ◽  
Shuzhen Yan ◽  
...  

Finding out how to overcome multistage biological barriers for nanocarriers in cancer therapy to obtain highly precise drug delivery is still a challenge.


2019 ◽  
Vol 7 (18) ◽  
pp. 2926-2937 ◽  
Author(s):  
Zeyu Xiao ◽  
Leung Chan ◽  
Dong Zhang ◽  
Cuiqing Huang ◽  
Chaoming Mei ◽  
...  

Herein we synthesize a cRGD peptide-conjugated PLGA nanosystem which is a high-efficiency drug-delivery platform for MR imaging-guided cancer theranostics.


2011 ◽  
Vol 12 (6) ◽  
pp. 2407-2415 ◽  
Author(s):  
Jinyao Liu ◽  
Yan Pang ◽  
Wei Huang ◽  
Zhaoyang Zhu ◽  
Xinyuan Zhu ◽  
...  

2018 ◽  
Vol 10 (24) ◽  
pp. 20256-20270 ◽  
Author(s):  
Arjun Prasad Tiwari ◽  
Tae In Hwang ◽  
Jung-Mi Oh ◽  
Bikendra Maharjan ◽  
Sungkun Chun ◽  
...  

2019 ◽  
Vol 6 (4) ◽  
pp. 711-716 ◽  
Author(s):  
Gang He ◽  
Sheng Chen ◽  
Yunjun Xu ◽  
Zhaohua Miao ◽  
Yan Ma ◽  
...  

A charge reversal induced colloidal hydrogel composed of amphoteric gelatin nanoparticles (Gela NPs) and melanin-like polydopamine nanoparticles (PDA NPs) was developed for synergistic cancer therapy.


2020 ◽  
Author(s):  
V. H. Giang Phan ◽  
Huu Thuy Trang Duong ◽  
Phu-Tri Tran ◽  
Thavasyappan Thambi ◽  
Duy-Khiet Ho ◽  
...  

2020 ◽  
Vol 56 (47) ◽  
pp. 6448-6451 ◽  
Author(s):  
Ming Gong ◽  
Jian Yang ◽  
Yongsheng Li ◽  
Jinlou Gu

A glutathione-responsive drug-delivery platform based on nanoMOFs was developed for selective cancer therapy through the introduction of disulfide bonds.


2019 ◽  
Vol 7 (5) ◽  
pp. 2152-2164 ◽  
Author(s):  
Tianqi Yi ◽  
Jun Huang ◽  
Xuewen Chen ◽  
Haiyun Xiong ◽  
Yang Kang ◽  
...  

Poly-puerarin, a novel biodegradable biomaterial as a drug delivery platform in anti-tumour therapy.


Sign in / Sign up

Export Citation Format

Share Document